Bristol Myers Squibb Co
BMY- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000014272
In the last 90 days, Bristol Myers Squibb Co insiders filed 0 open-market purchases and 3 sales; 2,541 institutions reported holding it in 13F filings for Q2 2026, worth $96.7B in total; no superinvestor holds it.
Other share classesCELG.RI
Key figures
- Market capClose on Nov 10, 2026
- $128.4B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $677.8K in total
- 3
- 13F holdersQ2 2026, +17 vs. previous quarter
- 2,541
- 13F valueReported value at the end of Q2 2026
- $96.7B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $48.2B
- −0.2% year over year
- Net income, FY2025
- $7.05B
- No comparable prior period
- Free cash flow, FY2025
- $12.8B
- −7.9% year over year
- Revenue, Q3 FY2026
- $13.1B
- +6.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 46.8M
- Shares sold short
- Change
- −3.10M
- −6.2% vs. previous
- Days to cover
- 4.24
- At average daily volume
Superinvestors holding BMY, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BMY at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Bristol Myers Squibb Co insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 (view filing)4:25 PM ET | Nov 5 | 1 day | Haller Julia ADirector | SSaleCommon Stock, $0.10 par value | −3.80K | $63.31 | −$240.6K | −11.2%30.3K after | |
| Sep 10, 2026 (view filing)4:37 PM ET | Sep 9 | 1 day | Massacesi CristianEVP,Chief Med Offr,Head of Dev | SSaleCommon Stock, $0.10 par value | −6.25K | $64.57 | −$403.5K | −25.0%18.7K after | |
| Aug 26, 2026 (view filing)4:17 PM ET | Aug 25 | 1 day | Holzer Phil MSVP and Controller | SSaleCommon Stock, $0.10 par value | −500 | $67.50 | −$33.8K | −2.9%16.9K after | |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −30.0K | $61.67 | −$1.85M | −15.9%159.2K after | 2 lots |
| Sep 3, 2025 (view filing) | Sep 2 | 1 day | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −56.0K | $47.33 | −$2.65M | −25.1%167.4K after | |
| Aug 5, 2025 (view filing) | Aug 2 | 3 days | Short Bartie WendyEVP, Corporate Affairs | SSaleCommon Stock, $0.10 par value | −378 | $44.23 | −$16.7K | −6.9%5.07K after | |
| May 13, 2025 (view filing) | May 9 | 4 days | Hickey BenjaminPresident, RayzeBio Org. | SSaleCommon Stock, $0.10 par value | −97.39 | $38.01 | −$3.70K | −100.0%0 after | |
| Apr 29, 2025 (view filing) | Apr 25 | 4 days | Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. | PPurchaseCommon Stock, $0.10 par value | +4.25K | $47.58 | +$202.2K | +5.4%83.5K after | |
| Feb 21, 2025 (view filing) | Feb 20 | 1 day | Boerner Christopher S.Chief Executive Officer | PPurchaseCommon Stock, $0.10 par value | +2.00K | $55.05 | +$110.1K | +1.9%104.6K after | |
| Feb 19, 2025 (view filing) | Feb 14 | 5 days | Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. | PPurchaseCommon Stock, $0.10 par value | +1.82K | $54.84 | +$100.0K | +2.9%63.9K after |
Top 10 13F holders, Q2 2026
See all 2,541 holdersThe largest institutional positions in Bristol Myers Squibb Co at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 180,384,994 | $10.4B | 0.15% | +8,702,106+5.1% | Added |
| Vanguard Capital Management LLC | 133,337,856 | $7.68B | 0.16% | +1,017,616+0.8% | Added |
| State Street Corp | 102,408,940 | $5.90B | 0.17% | +3,844,026+3.9% | Added |
| JPMorgan Chase & Co | 71,713,442 | $4.20B | 0.25% | −20,761,752−22.5% | Reduced |
| Charles Schwab Investment Management Inc | 67,595,177 | $3.89B | 0.52% | +6,479,804+10.6% | Added |
| Geode Capital Management, LLC | 56,443,077 | $3.24B | 0.17% | +1,156,903+2.1% | Added |
| Vanguard Portfolio Management LLC | 46,873,015 | $2.70B | 0.12% | +642,860+1.4% | Added |
| Norges Bank | 36,866,658 | $2.12B | 0.21% | +36,866,658 | New |
| Bank of America Corp | 34,045,352 | $1.96B | 0.13% | +1,458,371+4.5% | Added |
| Price T Rowe Associates Inc | 31,707,643 | $1.83B | 0.18% | +21,457,405+209.3% | Added |
Holders of 5% or more of BMY
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Bristol Myers Squibb Co.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 13G | 7.49%153.1M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.10%143.6M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| State Street Corp | 13G | 5.00%102.5M shares | New | Aug 7, 20261 filing | Aug 7, 2026 | SEC |
Politician trades
All politician trades in BMY28 members of Congress reported 73 trades in Bristol Myers Squibb Co since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 5, 2026 |  Tommy Tuberville Senate · AL | Sell (full) | $1K-$15K |
| Jul 21, 2026 |  Alan Armstrong Senate · OK | Buy | $1K-$15K |
| Jun 11, 2026 |  Mike Kelly House · PA | Sell | $15K-$50K |
| Jan 15, 2026 |  Julie Johnson House · TX | Sell | $1K-$15K |
| Jan 13, 2026 |  Julia Letlow House · LA | Buy | $1K-$15K |
Senate · AL · Aug 5, 2026
Sell (full)$1K-$15K
Senate · OK · Jul 21, 2026
Buy$1K-$15K
House · PA · Jun 11, 2026
Sell$15K-$50K
House · TX · Jan 15, 2026
Sell$1K-$15K
House · LA · Jan 13, 2026
Buy$1K-$15K